Organogenesis Holdings Inc
NASDAQ:ORGO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Organogenesis Holdings Inc
NASDAQ:ORGO
|
US |
|
Greggs PLC
LSE:GRG
|
UK |
|
Dare Bioscience Inc
NASDAQ:DARE
|
US |
|
Kinnate Biopharma Inc
F:6KB
|
US |
|
Adani Transmission Ltd
NSE:ADANITRANS
|
IN |
|
T
|
Toho Zinc Co Ltd
F:T62
|
JP |
|
Enviro-Hub Holdings Ltd
SGX:L23
|
SG |
|
Turk Prysmian Kablo ve Sistemleri AS
IST:PRKAB.E
|
TR |
|
Hycroft Mining Holding Corporation
NASDAQ:HYMC
|
US |
|
TCPL Packaging Ltd
NSE:TCPLPACK
|
IN |
|
A
|
Alpha Tau Medical Ltd
NASDAQ:DRTS
|
IL |
|
CarePayment Technologies Inc
OTC:CPYT
|
US |
|
P
|
PhilEnergy Co Ltd
KOSDAQ:378340
|
KR |
|
K
|
Kidswell Bio Corporation
TSE:4584
|
JP |
|
Aareal Bank AG
XETRA:ARL
|
DE |
|
D
|
DBM Global Inc
OTC:DBMG
|
US |
Organogenesis Holdings Inc
Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.
Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.
Record Q4 Revenue: Organogenesis reported record fourth quarter sales of $225.1 million, up 78% year-over-year and exceeding the high end of guidance.
Advanced Wound Care Surge: Advanced Wound Care product sales jumped 83% year-over-year in Q4, driving the strong results.
Profitability Up: Q4 operating income soared 519% to $63.3 million, and net income increased to $43.7 million from $7.7 million last year.
2026 Revenue Decline Expected: Management guided for a 25% to 38% revenue decline in 2026, with the steepest impact in the first half due to market confusion around CMS reimbursement policy changes.
Confidence in Recovery: Management expects sequential improvement in the second half of 2026 as market confusion resolves, with substantial market share gains and a return to positive adjusted EBITDA.
CMS Policy Impact: Recent CMS reforms favor PMA-approved products like Organogenesis', but late-2025 policy communication has caused clinical confusion and disrupted utilization.
